Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,433 | -16,339 | -69,456 | -47,524 | -29,957 |
| Depreciation Amortization | 676 | 334 | 1,427 | 1,120 | 777 |
| Accounts receivable | -1,262 | -1,312 | -453 | -936 | -1,071 |
| Other Working Capital | -16,338 | -12,334 | 29,243 | 25,729 | 27,129 |
| Other Operating Activity | 3,497 | 2,350 | 3,883 | 3,245 | 3,448 |
| Operating Cash Flow | $-46,860 | $-27,301 | $-35,356 | $-18,366 | $326 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 19,095 | 16,795 | -74,430 | -87,266 | -73,619 |
| PPE Investments | -976 | -117 | -512 | -358 | -267 |
| Investing Cash Flow | $18,119 | $16,678 | $-74,942 | $-87,624 | $-73,886 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25,159 | 20,417 | 31,814 | 20,730 | 11,598 |
| Financing Cash Flow | $25,159 | $20,417 | $31,814 | $20,730 | $11,598 |
| Exchange Rate Effect | 3 | 4 | -22 | -18 | N/A |
| Beginning Cash Position | 30,776 | 30,776 | 109,282 | 109,282 | 109,282 |
| End Cash Position | 27,197 | 40,574 | 30,776 | 24,004 | 47,320 |
| Net Cash Flow | $-3,579 | $9,798 | $-78,506 | $-85,278 | $-61,962 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,860 | -27,301 | -35,356 | -18,366 | 326 |
| Capital Expenditure | -976 | -117 | -512 | -378 | -287 |
| Free Cash Flow | -47,836 | -27,418 | -35,868 | -18,744 | 39 |